Abstract

ADVANCED IN NANOMEDICINE DRUG DELIVERY APPLICATION FOR HIV THERAPY

Khade Alka Balu*

Abstract

Despite remarkable advance with the current Highly active antiretroviral therapy (HAART) for HIV (Human immunodeficiency viruses) there remain challenges. HIV is a long term disease and patient adherence therapy is critical over a lifetime. Poor therapy adherence is associated with less effective viral suppression which risks the immediate health of the patient ,but also risk creating permanent treatment resistance to that particular group of agent within a given complication therapy regimen. Poor aqueous drug solubility is a vital limitation, negatively impacting oral bioavailability for many ART. Complete destruction resulting in recovering has been a center of research intention but the existence of cellular & anatomical regions. Where the virus can continue to replicate therapeutic drug concentration create sanctuary sites. Which reseed the blood when treatment is detached. Nanomedicine application can improve a variety of pharmacological problem from increasing bioavailability to specific targeting to the site of action. Often reducing the dose of drug need for the therapeutic activity. The application of nanomedicine to present & future HIV treatment may offer bespoke solution to the problem faced by established formulated drug. In this review we are discuss about the advance in nanomedicine drug delivery application for HIV therapy.

Keywords: Nanomedicine, HIV, HAART, ARV, Bioavailbility.